Buy Rating Affirmed: Immuneering's Lead Asset IMM-1-104 Shows Promise Despite Market Skepticism
TipRanksMay 2 15:25
Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.
Zhitong FinanceApr 12 18:40
Immuneering Analyst Ratings
BenzingaApr 12 18:31
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
TipRanksApr 12 18:30
Immuneering Analyst Ratings
BenzingaApr 2 19:49
Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence
TipRanksMar 29 16:26
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanksMar 19 13:40
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16
MT NewswiresMar 15 22:07
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating
MT NewswiresMar 15 20:13
Analysts Are Bullish on These Healthcare Stocks: 2seventy Bio (TSVT), Immuneering (IMRX)
TipRanksMar 15 19:00
Immuneering: Hold Rating Amidst Potential and Uncertainties in Drug Efficacy
TipRanksMar 15 18:46
Needham Maintains Buy on Immuneering, Lowers Price Target to $15
BenzingaMar 15 18:54
Immuneering Analyst Ratings
BenzingaMar 15 04:08
Immuneering Analyst Ratings
BenzingaMar 11 22:37
Needham Reiterates Buy on Immuneering, Maintains $20 Price Target
BenzingaMar 11 22:38
Immuneering's IMM-1-104 Progress Garners Buy Rating Amid Favorable Phase 2 Dose Determination and Anticipated Phase 1 Data
TipRanksMar 11 22:05
Immuneering Analyst Ratings
BenzingaMar 5 20:55
Analyst Maintains Buy Rating on Immuneering Amidst Promising Clinical Progress and Extended Cash Runway
TipRanksMar 5 14:28
Immuneering Analyst Ratings
BenzingaMar 4 18:35
Analysts Conflicted on These Healthcare Names: Immuneering (IMRX), Medtronic (MDT) and Gilead Sciences (GILD)
TipRanksMar 4 18:30
No Data
No Data